London-based biopharmaceutical company GW Pharmaceuticals is developing a cannabinoid prescription medicine called Epidiolex for the treatment of Dravet and Lennox-Gastaut Syndromes. In May GW Pharmaceuticals commenced a Phase 3 clinical trial of Epidiolex for the treatment of Lennox-Gastaut syndrome (LGS). In April, GW also initiated the second Phase 3 clinical trial of Epidiolex for the treatment of Dravet Syndrome. GW anticipates that topline data from both Phase 3 Epidiolex trials will be available in early 2016. www.gwpharm.com